Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUSTRAL trial of radiotherapy followed by durvalumab and ceralasertib for relapsed stage III NSCLC after PACIFIC
2024-515942-18-01Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jul 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and ceralasertib in non-small cell lung cancer (NSCLC), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Safety and tolerability and Progression-free survival. Started Jul 2025; status: completed.
02
Drugs
durvalumabceralasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515942-18-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515942-18-01.